MedTrace Logo

A Study to Assess the pharmacoMRI Effects of AUT00206 in Healthy Males

NCT02935725 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2017-11-27

No results posted yet for this study

Summary

A Phase 1, Single-centre, Double-blind, Placebo controlled Crossover Study to Assess the pharmacoMRI Effects of AUT00206 in Healthy Male Participants

Conditions

Interventions

DRUG

Low dose AUT00206 800mg

DRUG

High dose AUT00206 2000 mg

DRUG

Placebo

DRUG

Ketamine

OTHER

Saline

Sponsors & Collaborators

  • University of Manchester

    collaborator OTHER

  • Autifony Therapeutics Limited

    lead INDUSTRY

Principal Investigators

  • Bill Deakin, Prof · University of Manchester

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2017-11-30
Completion
2017-11-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02935725 on ClinicalTrials.gov